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ABSTRACT 
Objective: Coumarins and coumarin-related compounds are a plentiful source of potential drugs candidate in relation to its safety and efficacy. 
Hence, the present study was designed to evaluate the protective nature of Umbelliferone (UMB), a coumarin derivative on alterations in lipid 
metabolism during D-Galactosamine (D-GalN) and Lipopolysaccharides (LPS) induced Fulminant hepatic failure (FHF). 
Methods: Male wistar rats were challenged with a single intraperitoneal injection of D-GalN/LPS, and the protective nature of UMB was examined 
with reference to Total Cholesterol, Phospholipids, Triglycerides, free fatty acids(plasma, liver, and kidney), lipid metabolizing enzymes and 
lipoprotein fraction. 
Results: Anomalies in lipid status, lipid metabolizing enzymes and lipoprotein fractions induced by D-GalN/LPS was restored to near normal levels 
upon pretreatment with UMB which was further confirmed by Transmission electron microscopic observations. 
Conclusion: The outcome of the above findings evidenced the protective nature of UMB on alterations in lipid metabolism during D-GalN/LPS 
induced FHF in rats. 
Keywords: Umbelliferone, D-Galactosamine, Lipopolysaccharides (LPS), Lipid metabolism, Liver failure, Lipid metabolizing enzymes, Lipoproteins, 
Transmission electron microscope. 
 
INTRODUCTION 
Liver diseases pose a major threat to mankind worldwide today with 
limited options of prevention and treatment [1]. FHF synonymous 
with acute liver failure is an end-stage liver disease with a sudden 
onset of necrosis and massive degeneration of hepatocytes in the 
context of previously normal liver function [2]. FHF leads to 
multiorgan failure causing high mortality rates (80%-90%) despite 
the advent of liver transplantation, which is also limited by the 
chronic shortage of liver donors [3]. Several experimental models, 
contribute to develop therapeutic strategies by investigating the 
underlying mechanisms of liver dysfunction [4]. Among which, the 
combination of D-GalN and LPS is a widely established experimental 
model as it mimics the clinical FHF [5]. D-GalN, a well known 
hepatotoxicant renders its hepatotoxic effect via depletion of UTP 
and inhibition of mRNA synthesis and also has been suggested to 
react by activating hepatic macrophages to produce ROS. LPS, a toxic 
component of gram negative bacteria when co-administered with D-
GalN elicits immune response by stimulating inflammatory and 
hepatic kupfer cells to produce various proinflammatory cytokines 
thus implicated in the pathology of liver failure [6]. 
Coumarin, a benzopyrone compound is a plant-derived natural 
product widely distributed in numerous species belonging to 
different botanical families with the richest source being the 
Umbelliferae and Rutaceae families [7]. Despite the extensive 
distribution of coumarins in entire parts of the plant, the highest 
levels are consistently found in fruits followed by roots, stems and 
leaves [8]. They are also available in some essential oils such as 
cassia oil [9], cinnamon bark oil [10] and lavender oil [11]. The 
search for useful pharmaceutical has led to a resurgence of interest 
in coumarins because these substances display potent and relevant 
pharmacological activities that are structure-dependent, while at the 
same time appearing to lack toxicity in mammalian systems [12]. 
Umbelliferone (UMB) or 7-hydroxy coumarin, the major 
biotransformation product (75%) of coumarin is a widespread 
natural antioxidant with a short half-life [13] found predominantly 
in the edible fruits of golden apple (Aegle marmelos Correa) [14] 
and bitter orange (Citrus aurantium)[15]. It is a yellowish-white 
crystalline solid which has a slight solubility in hot water, but high 
solubility in ethanol [16]. UMB exhibits a wide spectrum of 
pharmaceutical effects including antioxidant [17], anti-lipidemic 
[18], anti-diabetic, anti-hyperglycemic [19], radioprotective [20] and 
anti-inflammatory properties [21]. Further, it has been used in the 
synthesis of anticancer drugs and in the treatment of asthma and 
allergic disorders. UMB can be invoked as a fluorescence indicator 
for metal ions such as copper and calcium and also serves as a pH 
indicator in the 6.5-8.9 range. [22].  
Fascinated by its diverse pharmacological properties, researchers 
trying to explore the pure coumarin and their derivatives for their 
applicability as drugs. Hence, the present study was aimed to 
evaluate the protective nature of UMB on lipid metabolism during D-
GalN/LPS induced Fulminant hepatic failure in rats.  
 
Fig. 1: Structure of Umbelliferone (C9H6O3
 
) 
MATERIALS AND METHODS 
Chemicals 
LPS (Escherichia coli, 0111: B4), D-GalN and Umbelliferone were 
purchased from Sigma Chemicals (St. Louis, MO, USA). All other 
chemicals used were of analytical grade obtained from Sisco 
Research Laboratories Pvt. Ltd, Mumbai, India. 
Animals 
Adult male albino rats of the Wistar strain weighing about 150-180g 
were utilized in this study. They were maintained in clean, sterile, 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491                 Vol 8, Issue 3, 2016 
Thiruvengadam et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 79-84 
 
80 
polypropylene cages and fed with commercial pelleted rat chow 
(M/s. Hindustan Lever Ltd., Bangalore, India), water ad libitum and kept 
in a well-ventilated room with 12 h light/dark cycles throughout the 
experimental period. All the experiments were designed and conducted 
according to the ethical norms approved by the institutional animal 
ethical committee guidelines. (IAEC. No.36/ 03/2014). 
Experimental design 
The experimental animals were divided into four groups with each 
groups comprising of six animals. 
Group 1 (Control) 
Normal control rats received 10% DMSO which served as a vehicle 
throughout the experimental period along with standard diet and 
drinking water.  
Group 2 (D-GalN/LPS) 
Rats received the standard diet and drinking water throughout the 
experimental period and were given single intraperitoneal injections 
of D-GalN (500 mg/kg body weight) and LPS (50 μg/kg body weight) 
[23] 24 h before the end of the experimental period. 
Group 3 (UMB+D-GalN/LPS 
Rats were pretreated with UMB (30 mg/kg body weight dissolved 
in10%DMSO) for 10 d prior to the induction of D-GalN/LPS 
Group 4 (UMB) 
Rats were treated with UMB (dissolved in10%DMSO) at a dosage of 
30 mg/kg body weight via intragastric intubation on all the days of 
the experimental period (10 d). 
At the end of the experimental period, i.e., 24h after the intraperitoneal 
injection of D-GalN/LPS the animals were fasted overnight and 
anesthetized with Ketamine (90 mg/kg) and Xylazine (10 mg/kg) and 
sacrificed by cervical decapitation. Blood was obtained from sinus 
orbital with and without anticoagulant for the separation of plasma 
and serum respectively. The liver and kidney tissue was excised 
immediately and washed with ice-cold saline. Accurately weighed liver 
and kidney were homogenized in 0.1M Tris HCl buffer and the 
homogenates was used for biochemical estimation. 
 
 




Total cholesterol [24], Phospholipids [25], Triglycerides [26] and free 
fatty acid [27] contents were estimated in plasma, liver and kidney. 
Free and ester cholesterol contents were assayed in plasma [24]. 
Estimation of lipid metabolizing enzymes 
The activity of lipoprotein lipase [28], Lecithin cholesterol 
acyltransferase [29] and hepatic triglyceride lipase [30] was 
estimated. 
Estimation of lipoprotein fractions 
Lipoproteins such as LDL, HDL and VLDL were fractionated from 
serum by dual precipitation technique [31]. 
Transmission electron microscopy of liver tissue 
A portion of the liver tissue was instantaneously immersed in 25 g/l 
of glutaraldehyde solution, buffered with 0.1 mol/l sodium 
cacodylate (pH 7.4). The specimen was subsequently placed in the 
buffer fixative medium, followed by washing with sodium cacodylate 
and fixation in 20 g/l osmium tetroxide buffered with 0.1 mol/l 
sodium cacodylate. After dehydration in a graded series of alcohol 
and propylene oxide, the tissues were transferred to propylene 
oxide: ethanol mixture (1:1) and embedded in resin. The specimens 
were placed on epoxy resin blocks and left in the oven at 65o
Fig. 3 and fig. 4 represents the effects of UMB on total cholesterol, 
phospholipids, triglycerides and free fatty acids in the liver and 
kidney of a normal and experimental group of rats. The levels of 
total cholesterol, triglycerides and free fatty acids were significantly 
elevated (p<0.05) while the levels of phospholipids were reduced in 
Group 2 D-GalN/LPS intoxicated rats when compared with Group 1 
control rats. UMB exhibited a characteristic property of significantly 
reducing the total cholesterol, triglycerides and free fatty acids 
levels and elevated the levels of phospholipids in Group 3 (UMB+D-
GalN/LPS) animals. Thus, UMB pretreatment significantly 
maintained the tissue lipids status at near normal levels as 
compared to the Group 2 rats. 
C for 72 
h. Thin sections were cut with an ultramicrotome, stained with 
uranyl acetate and lead citrate, and then examined on a TEM. 
Statistical analysis 
All the grouped data were evaluated with SPSS/22 software. 
Hypothesis testing methods included one-way analysis of variance 
(ANOVA) followed by Duncan’s multiple range test. P values of less 
than 0.05 were considered to indicate statistical significance. All these 
results were expressed as mean±SD for six animals in each group. 
RESULTS 
Effect of UMB on lipid status 
The levels of cholesterol (total, free and ester), phospholipids, 
triglycerides and free fatty acids in the plasma respectively are 
presented in table 1. Significant elevation of cholesterol (total, free and 
ester), triglycerides and free fatty acids with a reduction in the levels 
of phospholipids were observed in Group 2 rats injected with D-
GalN/LPS. These altered levels were brought back to near normal in 
Group 3 (UMB+D-GalN/LPS) animals. Group 4 UMB alone treated 
animals exhibited similar activity with that of Group 1 control animals. 
Table 1: Levels of cholesterol (Total, free and ester), phospholipids, triglycerides and free fatty acids in the plasma of control and 









Triglycerides Free fatty 
acids 
Group 1 (Control) 51.25±3.63 11.55±1.00 44.76±4.41 123.59±11.28 52.23±5.08 12.06±1.17 
Group 2 (D-GalN/LPS) 83.95±7.66 54.51±5.24a 22.76±2.19a 91.74±7.37a 151.19±13.95a 25.16±1.59
a 
Group 3 (UMB+D-GalN/LPS) 
a 
62.39±5.88 24.39±1.61a,b 35.54±2.70a,b 104.54±9.91a,b 72.43±6.00a,b 15.61±1.20a,b 
Group 4 (UMB) 
a,b 
51.37±3.83 11.66±0.68b,c 44.05±4.34b,c 123.04±11.06b,c 53.79±5.27b,c 12.04±1.18b,c b,c 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with agroup 1, bgroup 2 and cgroup 3 based 
on Duncan’s multiple range tests. Units: mg/dl 
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Fig. 3: Levels of total cholesterol, phospholipids, triglycerides and free fatty acids in the liver of control and experimental group of 
animals 
 
Fig. 4: Levels of total cholesterol, phospholipids, triglycerides and free fatty acids in the kidney of control and experimental group of 
animals 
 
Results are expressed as mean±SD for six rats in each group. 
Statistical significance at p<0.05 compared with agroup 1, bgroup 2 
and c
Altered lipid composition modifies the activity of lipid metabolizing 
enzymes which leads to striking changes in the pattern of integrated 
metabolism. Table 2 indicates the activity of the lipid metabolizing 
enzymes such as lecithin cholesterol acyl transferase, lipoprotein 
lipase in the plasma and hepatic triglyceride lipase in the liver of 
control and an experimental group of rats. A significant 
decrease(p<0.05) in the activities of these enzymes was noted in D-
GalN/LPS induced Group 2 rats while prior oral administration of 
UMB to Group 3 animals produces a significant reversal of the 
enzyme activity towards near normalcy. Group 4 animals treated 
with UMB alone exhibited similar activity with that of Group 1 
control animals. 
group 3 based on Duncan’s multiple range tests. 
Units: mg/g wet tissue 
Effect of UMB on lipid metabolizing enzymes 
 
Table 2: Activities of lipid metabolizing enzymes in the control and experimental group of animals 
Particulars Lipoprotein lipase Lecithin cholesterol acyltransferase Hepatic triglyceride lipase 
Group 1 (Control) 5.17±0.13 99.40±0.87 17.68±1.22 
Group 2 (D-GalN/LPS) 2.32±0.16 56.35±0.47a 10.02±0.73a 
Group 3 (UMB+D-GalN/LPS) 
a 
3.68±0.21 83.15±0.53a,b 14.59±1.18a,b 
Group 4 (UMB) 
a,b 
 5.41±0.40  99.85±0.92b,c 17.41±1.21b,c b,c 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with agroup 1, bgroup 2 and c
 
Lipoprotein fraction 
group 3 based 
on Duncan’s multiple range tests, Units: LPL-mmol of glycerol liberated/hr/ml plasma; LCAT-µg of cholesterol esterified/min/l of plasma; HTGL-µg 
of free fatty acid released/min/mg protein. 
As shown in table 3, significantly elevated levels (p<0.05) of LDL and 
VLDL with a concomitant reduction in HDL levels were obvious in 
Group 2 animals intoxicated with D-GalN/LPS. However, Group 3 
animals treated with UMB+D-GalN/LPS showed a substantial 
improvement in the levels of HDL with a parallel inhibitory action on 
the elevation of LDL and VLDL levels as compared to Group 2 D-
GalN/LPS animals. There was no marked difference between UMB 
alone Group 4 rats and Group 1 control rats. 
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Table 3: Levels of HDL, LDL and VLDL in the serum of control and experimental group of animals 
Particulars HDL LDL VLDL 
Group 1 (Control) 36.00±3.08 42.82±4.23 9.44±0.32 
Group 2 (D-GalN/LPS) 24.00±1.78 82.15±7.72a 14.83±1.13a 
Group 3 (UMB+D-GalN/LPS) 
a 
30.18±1.94 53.79±5.31a,b 12.42±1.04a,b 
Group 4 (UMB) 
a,b 
36.04±2.83 43.36±3.79b,c 9.32±0.23b,c b,c 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with agroup 1, bgroup 2 and c
 
group 3 based 
on Duncan’s multiple range tests. Units: mg/dl 
Findings on transmission electron microscopic images 
Intraperitoneal injection of D-GalN/LPS in Group 2 rats resulted in 
significant changes in liver morphology as evidenced from fig.5A, 
showing accumulation of assorted lipid droplets with swollen 
mitochondria. It is very clear from Fig.5B, that UMB+D-GalN/LPS 
treated Group 3 rat livers showed meager lipid droplet with 
serrated edged nucleus and scanty swollen mitochondria. 
 
 
Fig. 5: Transmission electron microscopic observations of D-
GalN/LPS intoxicated rat liver (A), and UMB+D-GalN/LPS 
treated rat liver (B) 
 
A-Group 2 D-GalN/LPS intoxicated rat livers with arrows indicating 
swollen mitochondria and (L) assorted lipid droplets. B-Group 3 
UMB+D-GalN/LPS treated rat liver with meager lipid droplets and 
scanty mitochondria. 
DISCUSSION 
The liver is the major site for the synthesis and metabolism of 
cholesterol, bile acids and phospholipids [32]. Marked alterations in 
lipid metabolism have been declared in D-GalN induced hepatic 
injury in rats [33] which corroborates well with the present 
investigation. Any liver disease will show an increased blood 
cholesterol level [34]. The sizable increase of cholesterol in the 
plasma, liver and kidney sample might have been due to the inability 
of the diseased liver to remove cholesterol from circulation. This 
finding could be related to the results of the previous studies [35]. 
The administration of D-GalN/LPS causes the imbalance between 
the rate of synthesis and the rate of release of triglycerides by the 
parenchymal cells into the circulation [36] and also elevates the 
levels of intracellular calcium. These changes in lipid metabolism led 
to the accumulation of triglycerides and free fatty acids. The 
elevated triglyceride and free fatty acids levels in the plasma, liver 
and kidney sample of rats found in the present study are in 
accordance with the previous report that showed a parallel increase 
in the lipid levels in D-GalN/LPS intoxicated rats [37]. Phospholipids 
are vital components of bio membranes rich in polyunsaturated 
fatty acids, which are a susceptible substrate for free radicals and 
also important for the maintenance of cellular integrity, 
microviscosity, and survival [38]. The significant decrease in the 
levels of phospholipids in the plasma, liver and kidney of D-
GalN/LPS intoxicated rats may be explained by the accelerated 
degradation of membrane phospholipids probably by the activation 
of phospholipase A2 activity as a consequence of intracellular 
calcium overload [39]. Rats pretreated with UMB prior to the 
induction of hepatic damage showed a restoration of the altered 
lipid levels induced by D-GalN/LPS towards near normalcy thereby 
showing the modulating effect of UMB against D-GalN/LPS induced 
changes in the lipid levels in rats. 
The lipid metabolizing enzymes such as lipoprotein lipase, lecithin 
cholesterol acyltransferase and hepatic triglyceride lipase are the 
key players involved in lipoprotein metabolism. LPL activity varies 
within tissues depending upon the nutritional and stress state of an 
animal. LPL is associated with the initial catabolism of triglyceride-
rich lipoproteins, VLDL and chylomicron by the extrahepatic tissues 
[40]. Thus, decreased activity of LPL indicates decreased uptake of 
these lipoproteins by the tissues resulting in hypertriglyceridemia in 
D-GalN/LPS induced rats. Among the activities most drastically 
decreased after D-GalN/LPS challenge is that of plasma LCAT. This 
deficiency leads to low levels of plasma cholesterol esters and in 
severe damage, the fall in cholesterol ester content in the plasma 
was attributed to the lack of LCAT[35]. Earlier reports are also 
proposed that D-GalN injection results in severe LCAT deficiency in 
rats [41]. HTGL is allegedly a role in the catabolism of VLDL and 
chylomicron remnants. The efficient clearance of VLDL and 
chylomicron from circulation by the liver requires the action of 
HTGL. Hence reduced activities of hepatic lipase results in increased 
accumulation of lipoproteins (LDL, VLDL) and triglycerides in the 
liver [42]. The activities of above lipid metabolizing enzymes were 
reverted to near normal upon pretreatment with UMB. This assures 
the hypolipidemic effect of UMB. 
HDL, beneficial lipoprotein helps in the scavenging of cholesterol 
from the extrahepatic tissues in the presence of LCAT and brings it 
to the liver. The lowered HDL levels can be ascribed to decreased 
serum LPL and LCAT activity. In this context, it has been 
demonstrated that elevated activity of plasma LPL leads to an 
increase in HDL production and reduction in LDL constituents [43]. 
It has clearly been shown that a relationship exists between 
increased concentration of HDL-C and decreased morbidity and 
mortality rate in cardiovascular patients [44]. Similarly, recent 
research has revealed that a 4-5% decrease in LDL-cholesterol 
results in a 5-10% decrease in the occurrence of coronary heart 
disease (CHD) [45]. Numerous studies have already reported the 
increased levels of LDL,VLDL and a concomitant reduction in the 
HDL values during D-GalN/LPS induced liver failure [38, 46]. Our 
present findings clearly coincide with the above findings. The ability 
of UMB to normalize the abnormal levels of lipoproteins during D-
GalN/LPS liver failure in our investigation justifies the foregoing 
findings and confirms its anti dyslipidemic effect.  
Intraperitoneal injection of D-GalN/LPS in rats resulted in significant 
changes in liver morphology. As shown in Fig.5A assorted lipid 
droplets with swollen mitochondria and polymorphic mitochondria 
were evident. These alterations in liver cell morphology and 
appearance of lipid droplets were consistent with the severe 
alterations in the lipid profile. The appearance of severe 
degeneration of mitochondria could be caused by severe depletion 
of glutathione and other non-enzymatic antioxidants. 
CONCLUSION 
The results of the present investigation clearly suggests that UMB is 
able to influence lipid metabolism by restoring the altered levels of 
lipids status and lipid metabolizing enzymes and stabilizing the 
derangement of lipoprotein levels during experimentally induced 
hepatic failure. The anti dyslipidemic effect of UMB during D-
GalN/LPS induced fulminant hepatic failure may be attributed due to 
its ability to combat the oxidative stress and or the involvement of 
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some cellular regulatory mechanism that preserves the cellular 
integrity against chemically induced toxicity. However, further dose 
dependent and mechanistic studies could eventually reinforce its 
use in modern medicine as a remedy for lipid-associated disorders. 
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